Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

nCovid-19 in 2020: From Despair to Hope

Author(s): Ravi Varala* and Haribabu Bollikolla

Volume 1, Issue 1, 2020

Page: [9 - 12] Pages: 4

DOI: 10.2174/2666796701999200621202839

Abstract

Outbreak mentioned in China in December 2019 has spread rapidly across 220 countries infecting more than 6.8 million people and killing nearly about 0.4 million people across the world and is declared as ‘pandemic’ by WHO. In this perspective, authors have presented a brief overview of Covid- 19 from its origin to transmission and the measures to be taken to restrict the outbreak of this evil virus. Medical diagnosis offers some promising drug combinations for treating the infected patients effectively, although with some side effects. Research is currently in progress, giving us the hope of getting a viable and safe vaccine.

Keywords: Corona virus, pandemic, origin, transmission, symptoms, testing, treatment and management.

[1]
Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019 N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status Mil Med Res 2020; 7(1): 11.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 32169119]
[3]
International Committee on Taxonomy of Viruses. Virus Taxonomy 2018. https://talk.ictvonline.org/taxonomy/
[4]
Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 2020 181(2): 223-7.
[http://dx.doi.org/10.1016/j.cell.2020.03.035] [PMID: 32220310]
[5]
Gross M. Feature virus outbreak crosses boundaries. Curr Biol 2020; 30: 191-4.
[http://dx.doi.org/10.1016/j.cub.2020.02.049]
[6]
Lam TTY, Shum MHH, Zhu HC, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. Nature 2020.
[http://dx.doi.org/10.1101/2020.02.13.945485]
[7]
Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID‐19 Coronavirus (SARS‐CoV‐2) based on SARS‐CoV immunological studies. Viruses 2020; 12(3): 254-68.
[http://dx.doi.org/10.3390/v12030254] [PMID: 32106567]
[8]
Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein ofSARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Nature Commu 2020; 11: 1620-31.
[9]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[10]
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382(16): 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[11]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[12]
Centre for Disease Control & Prevention. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
[13]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment Coronavirus (COVID-19) StatPearls https://www.ncbi.nlm.nih.gov/books/NBK554776/
[14]
Bauchner H, Fontanarosa PB, Livingston EH. Conserving supply of personal pequipment-A call for ideas. JAMA 2020; 323: 19.
[http://dx.doi.org/10.1001/jama.2020.4770] [PMID: 32196543]
[15]
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges J Microbiol Immunol Infect 2020; 53(3): 436-43.
[http://dx.doi.org/10.1016/j.jmii.2020.03.034] [PMID: 32307245]
[16]
Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human Coronavirus diseases. ACS Cent Sci 2020; 6(3): 315-31.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[17]
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020; 52(4): 583-9.
[http://dx.doi.org/10.1016/j.immuni.2020.03.007] [PMID: 32259480]
[18]
Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 Pandemic. Trends Pharmacol Sci 2020; 41(6): 363-82.
[http://dx.doi.org/10.1016/j.tips.2020.03.006] [PMID: 32291112]
[19]
Gomeni R, Xu T, Gao X, Bressolle-Gomeni F. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. J Pharmacokinet Phar 2020.
[20]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronoviruse disease (Covid 19)-A Review. JAMA 2020; 323(18): 1824-6.
[http://dx.doi.org/10.1001/jama.2020.6019] [PMID: 32282022]
[21]
Bergman SJ, Cennimo DJ, Miller MM, Olsen KM, Windle ML. Treatment of Coronavirus Disease 2019 (COVID-19). Investigational Drugs and Other Therapies 2020.

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy